Items Tagged ‘PARP2’

September 6th, 2016

FDA Accepts Priority Review of Rucaparib For The Treatment Of Advanced Mutant BRCA Ovarian Cancer


The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to the application for the treatment of advanced ovarian cancer in patients with deleterious BRCA-mutated cancers. Rucaparib was granted Breakthrough Therapy Designation by the FDA in April 2015. About Ovarian Cancer […]

View full entry

Tags: Breakthrough Therapy Designation, News, Ovarian Cancer, PARP1, PARP2, PARP3, Stage II-IV Ovarian Cancer